<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H728080C6BC7944EC86B387B7308CB91E" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 2009 IH: Removing Barriers to Allergy Diagnostic Testing Act of 2019</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2019-04-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2009</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20190401">April 1, 2019</action-date><action-desc><sponsor name-id="C001067">Ms. Clarke of New York</sponsor> (for herself and <cosponsor name-id="U000031">Mr. Upton</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro
			 specific IgE tests and percutaneous tests for allergies under the Medicare
			 and Medicaid programs, and for other purposes.</official-title></form>
	<legis-body id="H709ECD49732D45A89DB8797CF17DA82E" style="OLC">
 <section id="HBE2223CD8F8545BFB56D257DA59C0C81" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Removing Barriers to Allergy Diagnostic Testing Act of 2019</short-title></quote>.</text> </section><section id="H2E58039B2E334CF9BAD418FBCF6DB088" section-type="subsequent-section"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
 <paragraph id="HCA908768A8BC4D83A636628B82CF43BD"><enum>(1)</enum><text>Allergies, when not properly diagnosed, cannot be effectively treated.</text> </paragraph><paragraph id="HAD966A4EFCDA421282C1A85FEA5C2D3D"><enum>(2)</enum><text>Allergies to food, inhaled particles, or other sources can cause debilitating and, in some cases, fatal reactions.</text>
 </paragraph><paragraph id="H0211839E487A4AD29E0E91FA43424A5A"><enum>(3)</enum><text>Allergies can substantially compound other illnesses, including asthma, emphysema, and adult obstructive pulmonary diseases, leading to social and economic costs for families and our Nation’s health care system.</text>
 </paragraph><paragraph id="HB1F39D8DA20D4C68ABBCEC9D38A186A4"><enum>(4)</enum><text display-inline="yes-display-inline">According to clinical guidelines from the National Institutes of Health and recommendations from peer-reviewed literature, in vitro specific IgE tests and percutaneous tests are considered equivalent as confirmatory tests in terms of their sensitivity and accuracy.</text>
 </paragraph><paragraph id="H24ACF440EE3247A08C342EE549EB7359"><enum>(5)</enum><text display-inline="yes-display-inline">Despite these recommendations, some current Medicare local coverage determinations and Medicaid coverage policies deny equal access to in vitro specific IgE tests and percutaneous tests.</text>
 </paragraph><paragraph id="H0410D80EB05346BB81EE31BD3A9C0298"><enum>(6)</enum><text display-inline="yes-display-inline">In vitro specific IgE tests and percutaneous tests must be equally accessible for clinicians and patients to improve health outcomes, reduce system costs, and reduce current health care disparities caused by the lack of equal coverage.</text>
			</paragraph></section><section id="HA3F5AB96E8D74892ACC90C1EDF6E7527"><enum>3.</enum><header>Medicaid coverage for allergy diagnostic testing services</header>
 <subsection id="H8BC1665AE76444C48FA5BCDF6FC3ADF9"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Title XIX of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396</external-xref> et seq.) is amended—</text> <paragraph id="HAFA07A8DF4B243F48F7A1C19D35BDFAD"><enum>(1)</enum><text>in section 1902(a)—</text>
 <subparagraph commented="no" id="H35772BC65DED4021A12E2575200EC11B"><enum>(A)</enum><text>in paragraph (85), by striking <quote>and</quote> at the end;</text> </subparagraph><subparagraph commented="no" id="HDB74495491CD4A84A6DCEFDEA743BA4C"><enum>(B)</enum><text>in paragraph (86), by striking the period at the end and inserting <quote>; and</quote>; and</text>
 </subparagraph><subparagraph commented="no" id="HB0148E49CDEA4C76B53DAA23C1393272"><enum>(C)</enum><text>by inserting after paragraph (86) the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="H5DF0880D87D847FC838072500A1E80E7" style="OLC"> <paragraph commented="no" id="H9285A8F2D00A4DB79ACFE48601BEB25A"><enum>(87)</enum><text display-inline="yes-display-inline">provide, with respect to the provision of allergy diagnostic testing services (as defined in section 1905(ee)) under the State plan, for equality in the treatment of in vitro specific IgE tests and percutaneous tests with respect to—</text>
 <subparagraph commented="no" id="H8D0BFFE103774F009D16F2E7E3EFF652"><enum>(A)</enum><text>any medical necessity or other coverage requirements established for such in vitro specific IgE and percutaneous tests;</text>
 </subparagraph><subparagraph commented="no" id="H7341665F674149A08ED269331211816A"><enum>(B)</enum><text>any frequency limits established for such tests; and</text> </subparagraph><subparagraph commented="no" id="H17DA69E30F9F498C8041B5DAA7806D09"><enum>(C)</enum><text display-inline="yes-display-inline">any allergen unit limits established for such tests.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HD720BF6D61444959BE9A466ACB750184"><enum>(2)</enum><text>in section 1905—</text> <subparagraph id="HBC8322CCF8A24C49BBC136831FCDAD76"><enum>(A)</enum><text>in subsection (r)—</text>
 <clause id="H3C492323D8A54C0A938B266584D469B1"><enum>(i)</enum><text>by redesignating paragraph (5) as paragraph (6); and</text> </clause><clause id="HEC70F9902960447DB6D327F1B1AFDF0C"><enum>(ii)</enum><text>by inserting after paragraph (4) the following new paragraph:</text>
							<quoted-block display-inline="no-display-inline" id="H7CB13D26B80C4637829DA9A78F15AB4F" style="OLC">
 <paragraph id="H95A7F877F54D40999902BA0CDE7D1991"><enum>(5)</enum><text display-inline="yes-display-inline">Allergy diagnostic testing services (as defined in subsection (ff)).</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block> </clause></subparagraph><subparagraph id="H985F324FB04B4477AF9C99D096ED3739"><enum>(B)</enum><text>by adding at the end the following new subsection:</text>
						<quoted-block display-inline="no-display-inline" id="HB06540F44E71423BB5A657A75E20B45A" style="OLC">
 <subsection id="HCDCB06D0DF944C139C72C54389C59D06"><enum>(ff)</enum><header>Allergy diagnostic testing services defined</header><text display-inline="yes-display-inline">The term <term>allergy diagnostic testing services</term> means in vitro specific IgE tests and percutaneous tests that—</text> <paragraph id="H996EA723083D41CEB1334348327D7016"><enum>(1)</enum><text>have been cleared under section 501(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and</text>
 </paragraph><paragraph id="H10D564DB28F54792AD7689BE3D2417E9"><enum>(2)</enum><text>are provided to individuals for the purpose of evaluating immunologic response to certain antigens.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </subparagraph></paragraph></subsection><subsection id="H19F3B0D5B91040AABD680E9F7D424F4A"><enum>(b)</enum><header>Effective date</header> <paragraph id="H7B03C24EE5164762858024EAAFA498C6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to paragraph (2), the amendments made by this section shall apply with respect to items and services provided on or after January 1, 2021.</text>
 </paragraph><paragraph id="H801A5DAE0D254CE29E64EDF35769CE3E"><enum>(2)</enum><header>Exception for State legislation</header><text display-inline="yes-display-inline">In the case of a State plan under title XIX of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396</external-xref> et seq.) that the Secretary of Health and Human Services determines requires State legislation in order for the respective plan to meet any requirement imposed by amendments made by this section, the respective plan shall not be regarded as failing to comply with the requirements of such title solely on the basis of its failure to meet such an additional requirement before the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that begins after the date of the enactment of this Act. For purposes of the previous sentence, in the case of a State that has a 2-year legislative session, each year of the session shall be considered to be a separate regular session of the State legislature.</text>
				</paragraph></subsection></section><section commented="no" id="H1E5CDA4503084C6C9603363BB36BBE2A"><enum>4.</enum><header>Medicare coverage for allergy diagnostic testing services</header>
 <subsection id="H9C90CAA5927D425E85AF739191E72C76"><enum>(a)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended—</text> <paragraph id="H58D8BF945B74448192F069923DF71F27"><enum>(1)</enum><text>in subsection (s)(2)—</text>
 <subparagraph commented="no" id="H3C6B691D58C6407EA558AFEE6F6C0CAC"><enum>(A)</enum><text>in subparagraph (GG), by striking <quote>and</quote> at the end;</text> </subparagraph><subparagraph commented="no" id="HCA6BCA6A28B04CF682AD3D08925D5144"><enum>(B)</enum><text>in subparagraph (HH), by striking the period at the end and inserting <quote>; and</quote>; and</text>
 </subparagraph><subparagraph commented="no" id="H59F90AA31BEF4003AB5C60081D9A1BF7"><enum>(C)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="H7C6693A145D846DBB942A15437975AAC" style="OLC"> <subparagraph commented="no" id="H1948F0D4353144F4A7FBEEF972B34569" indent="up1"><enum>(II)</enum><text display-inline="yes-display-inline">allergy diagnostic testing services (as defined in subsection (kkk));</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="H53A3248350544053BBD2A2D75046A3A5"><enum>(2)</enum><text>by adding at the end the following new subsection:</text> <quoted-block display-inline="no-display-inline" id="H092A6FF25CD847F18E10872B36F65F89" style="OLC"> <subsection commented="no" id="H8B015183DB5947D18C5CE8C4952668FA"><enum>(kkk)</enum><header>Allergy diagnostic testing services</header> <paragraph commented="no" id="HBB6A4BA9447048418686775A2ABA32A2"><enum>(1)</enum><header>In general</header><text>The term <term>allergy diagnostic testing services</term> means in vitro specific IgE tests and percutaneous tests—</text>
 <subparagraph commented="no" id="H7846C182915C4D409000C6E67287EB7E"><enum>(A)</enum><text display-inline="yes-display-inline">that have been cleared under section 501(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and</text>
 </subparagraph><subparagraph commented="no" id="H5DC35C6A360F4116B148BF07BA041092"><enum>(B)</enum><text display-inline="yes-display-inline">which are furnished to individuals for the purpose of evaluating immunologic response to certain antigens, as determined appropriate by the practitioner ordering such test.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HF797456D167B46DEA2160624EAE4080A"><enum>(2)</enum><header>Equal access to testing methods</header><text display-inline="yes-display-inline">The Secretary shall ensure equality in the treatment of in vitro specific IgE tests and percutaneous tests described in paragraph (1) with respect to—</text>
 <subparagraph commented="no" id="HB2EBF573508F466289D792F7DECF23FE"><enum>(A)</enum><text>any medical necessity or other coverage requirements established for such in vitro specific IgE and percutaneous tests;</text>
 </subparagraph><subparagraph commented="no" id="H469D079D47174919AE96F90AEE63FF33"><enum>(B)</enum><text>any frequency limits established for such tests; and</text> </subparagraph><subparagraph commented="no" id="H469DDB8DDD3C4FBEA7A8E9E7411E4BAF"><enum>(C)</enum><text display-inline="yes-display-inline">any allergen unit limits established for a year for such tests.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H4A440966EEC34B74BD61BAC654FF5584"><enum>(b)</enum><header>Payment</header><text display-inline="yes-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text>
				<quoted-block display-inline="no-display-inline" id="H6DF5F8A95C9749BD9E5928DD7E6EA2EE" style="OLC">
 <subsection id="HFE0712D1EA574A41BCEAE5396689C40B"><enum>(x)</enum><header>Allergy diagnostic testing services</header><text display-inline="yes-display-inline">For purposes of payment only, in the case of allergy diagnostic testing services (as defined in section 1861(jjj))—</text>
 <paragraph id="HF81D9D8EA9E9421BADBE28E5B8EDA478"><enum>(1)</enum><text>in vitro specific IgE tests shall be treated as clinical diagnostic laboratory tests; and</text> </paragraph><paragraph id="HABE6217174F048EBA416C1C45197E38B"><enum>(2)</enum><text>percutaneous tests shall be treated as physicians’ services.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H3BD13973EA9F4B1AA4A5CEA6DCEA34BA"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply with respect to items and services furnished on or after January 1, 2021.</text>
			</subsection></section></legis-body></bill>


